CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Persistent or Recurrent Stress Urinary Incontinence Following Surgical Treatment
Latest Information Update: 15 Nov 2024
Price :
$35 *
At a glance
- Drugs Iltamiocel (Primary)
- Indications Stress incontinence
- Focus Registrational; Therapeutic Use
- Acronyms CELLEBRATE
- Sponsors Cook MyoSite
- 08 Feb 2024 Planned number of patients changed from 260 to 96.
- 14 Apr 2022 Planned number of patients changed from 320 to 260.
- 14 Apr 2022 Planned End Date changed from 1 Sep 2023 to 1 Feb 2026.